- Provided contract manufacturing restructuring analytics and exit strategy for private label OTC brand held captive by underperforming CMO with 90%+ of unit volume. Strategy centered on CMO diversification of 200 SKU portfolio derisking business, increasing service levels, and reducing COGS by 12%.- Adviser to middle market health care centric private equity firm on potential acquisitions including detailed operations and financial diligence for multiple target companies. - Developed and launched industry leading web based subscription service in the healthcare and fitness sector with a quick and successful exit of minority interest to the primary equity owner.

Completed Management LBO from private equity in 2017. As CEO of Letco Medical, led successful exit in 2022 to Fagron Inc., FAGR (EBR) the largest publicly traded global compounding supply company based in the Netherlands. Return on initial investment during the hold period exceeded 6x.

Key member of Harvard Drug Group Executive Team that assisted private equity ownership in exiting five sperate brands and businesses to Cardinal Health in 2015 for $1.2B generating a return on initial investment of more than 7x over the 5 year hold period. CAH (NYSE).